CSTL News and Press, Castle Biosciences Inc. From 02/05/26

FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the clo...

2026-02-04 08:35:00 ET ... Read the full article on Seeking Alpha For further details see: Wasatch Micro Cap Fund Q4 2025 Performance Review

2026-02-03 17:20:03 ET On Feb. 2, 2026, AIGH Capital Management LLC reported a complete sale of its Lumen Technologies (NYSE:LUMN) stake, with an estimated transaction value of $15.61 million based on quarterly average pricing. According to an SEC filing dated Feb. 2, 2026, ...

2026-01-29 16:04:38 ET Paul Knight from KeyBanc issued a price target of $50.00 for CSTL on 2026-01-29 20:40:30. The adjusted price target was set to $50.00. At the time of the announcement, CSTL was trading at $39.16. The overall price target consensus is at $49.75 with...

2026-01-29 15:15:03 ET KeyBanc analyst issues OVERWEIGHT recommendation for CSTL on January 29, 2026 08:40PM ET. The previous analyst recommendation was Overweight. CSTL was trading at $39.16 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 37% over 2024 Year-end 2025 cash, cash equivalents a...

2025-12-22 07:06:10 ET from Canaccord Genuity issued a price target of $50.00 for CSTL on 2025-12-22 11:54:26. The adjusted price target was set to $50.00. At the time of the announcement, CSTL was trading at $39.44. The overall price target consensus is at $50.00 with h...

FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing (NGS)-b...

FRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new systematic review and meta-analysis (SRMA) demonstrating that the TissueCypher &#x...

FRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent expert consensus paper titled “31-Gene Expression Profiling for Cuta...